Gen1E-1124 is under clinical development by GEn1E Lifesciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

ULSCs is under clinical development by RESTEM and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

ARDS survival was significantly predicted by improvement in the P/F ratio in patients who underwent 3 periods of prone ...

Sepsis, a severe and often fatal complication of infection, is a leading cause of both ALI and acute respiratory distress ...

Sepsis, a severe and often fatal complication of infection, is a leading cause of both acute lung injury (ALI) and acute ...

This is the first randomized controlled trial investigating the efficacy and safety of low-dose prolonged methylprednisolone administration in early ARDS. This study tested a pathophysiologic ...

Ozone therapy offers new hope for sepsis-induced lung injury by improving lung function and survival through enhanced ...

Healios KK (JP:4593) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street analysts, ...